molecular-profiling
(2)
BostonGene
BostonGene is a Waltham, Massachusetts biotechnology company that applies AI-driven multiomics to cancer. Its Tumor Portrait platform integrates DNA and RNA sequencing with immune and tumor-microenvironment analysis into a single test, producing molecular profiles that help oncologists select therapies and help pharmaceutical partners design trials, identify biomarkers, and accelerate drug development. Founded in 2015 and led by CEO Andrew Feinberg, the company reached unicorn status in 2022.
Stellaromics Inc.
Stellaromics is a Boston-based spatial biology company building tools that map gene expression in three dimensions inside intact tissue. Spun out of the labs of Karl Deisseroth (Stanford) and Xiao Wang (MIT/Broad Institute), the company commercializes its Pyxa platform, which uses proprietary STARmap and RIBOmap chemistry to deliver multiplexed 3D spatial transcriptomics and translatomics in tissue sections up to 100 microns thick at subcellular resolution. It targets researchers in neuroscience, oncology and immunology who need to preserve native tissue architecture rather than rely on flat 2D thin-section methods.